Adagene Inc. has 10 Schedule 13D or 13G filings on record since 2025-07-02. 4 holders' latest filing reports 5% or more of ordinary shares, par value us$0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Peter Luo | 11.2% | 6,242,998 | SCHEDULE 13D/A, 2026-06-08 | 2026-06-05 |
| Janus Henderson Group Plc | 10.1% | 6,666,666 | SCHEDULE 13G, 2026-05-07 | 2026-04-30 |
| Smith Vincent C | 8.7% | 5,095,351 | SCHEDULE 13G/A, 2026-01-29 | 2025-12-31 |
| Chernett Jorey | 5.1% | 2,389,060 | SCHEDULE 13G, 2026-03-18 | 2026-03-16 |
| Panacea Venture Healthcare Fund II, L.P. | 3.8% | 2,250,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| WuXi PharmaTech Healthcare Fund I L.P. | 3.5% | 2,891,594 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Fmr LLC | 0.9% | 473,949 | SCHEDULE 13G/A, 2025-07-02 | 2025-06-30 |
| General Atlantic Singapore Fund Pte. Ltd. | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Purpose of Transaction (Item 4)
Peter Luo
On May 23, 2025, Mr. Luo received 191,667 ordinary shares from Great Han Fortune LP for the benefit of Peter Luo, and Xiaohong She received 23,333 ordinary shares from Great Han Fortune LP for the benefit of Xiaohong She. On May 23, 2025, Mr. Luo and Xiaohong She transferred 191,667 and 23,333 ordinary shares respectively to HAN 2020 Irrevocable Trust, for estate planning purpose. Due to the operation of the Concert Party Agreement dated December 14, 2020 among members of Peter Luo-Acting-in-Concert-Group, Peter Luo may be deemed to acquire or dispose additional beneficial ownership from time to time due to the acquisition or disposal of beneficial ownership by the members of Peter Luo-Acting-in-Concert-Group. The Reporting Persons acquired the ordinary shares reported herein for investment and estate planning purposes, in the ordinary course of business. Other than as disclosed in this Amendment, the Reporting Persons currently do not have any plans or proposals that would result in or relate to any of the transactions or changes listed in Items 4(a) through 4(j) of the Schedule 13D. Mr. Luo is the Chief Executive Officer and the Chairman of the Board of Directors of the Issuer. The Reporting Persons, including members of the Peter Luo-Acting-in-Concert-Group, may acquire additional ordinary shares in the ordinary course of business, including in connection with outstanding options or additional options to be granted by the Issuer to Mr. Luo and/or share repurchase plan …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-08; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-02 | Fmr LLC | 0.9% | SCHEDULE 13G/A |
| 2025-11-14 | Panacea Venture Healthcare Fund II, L.P. | 3.8% | SCHEDULE 13G/A |
| 2025-11-14 | WuXi PharmaTech Healthcare Fund I L.P. | 7% | SCHEDULE 13G/A |
| 2026-01-29 | Smith Vincent C | 8.7% | SCHEDULE 13G/A |
| 2026-02-17 | General Atlantic Singapore Fund Pte. Ltd. | 0% | SCHEDULE 13G/A |
| 2026-03-18 | Chernett Jorey | 5.1% | SCHEDULE 13G |
| 2026-05-07 | Janus Henderson Group Plc | 10.1% | SCHEDULE 13G |
| 2026-05-15 | WuXi PharmaTech Healthcare Fund I L.P. | 5.9% | SCHEDULE 13G/A |
| 2026-06-08 | Peter Luo | 11.2% | SCHEDULE 13D/A |
| 2026-08-14 | WuXi PharmaTech Healthcare Fund I L.P. | 3.5% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Adagene Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.